Resmetirom Linked to Lower Heart Risks Than Semaglutide
In a new comparative analysis, patients taking resmetirom for MASH had lower rates of major cardiovascular events than those on semaglutide.
Updated on Oct. 12, 2026 in Heart Disease
Live Poll
Do new clinical study results regarding heart disease benefits increase your trust in chronic condition treatments?
A large propensity-matched analysis presented at the 2026 American College of Gastroenterology Annual Scientific Meeting found that resmetirom patients had lower risks of major adverse cardiovascular events (MACE) and all-cause mortality compared to those taking semaglutide. This study focused on adults with MASLD or MASH and existing hepatic fibrosis.
Why it matters
This comparison addresses a critical gap in clinical data for patients managing liver disease alongside cardiovascular risks. Understanding how these therapies influence heart health can help clinicians and patients make more informed decisions regarding treatment options for those with metabolic liver conditions.
Researchers utilized the TriNetX Global Collaborative Network to compare outcomes among 8,506 patients. While resmetirom was linked to a significant reduction in MACE and mortality over two years, the findings represent a retrospective analysis that does not determine causality.
The players
American College of Gastroenterology
A professional medical society that promotes clinical research and education in digestive health and liver conditions.
The details
The investigators matched patients based on demographics, cardiovascular risk factors, and metabolic comorbidities to minimize selection bias. Resmetirom, which received FDA approval for noncirrhotic MASH in March 2024, functions as a thyroid hormone receptor-beta agonist. Semaglutide, approved for the MASH population in August 2025, acts as a GLP-1 receptor agonist. The study evaluated these distinct pathways to see how they impact cardiovascular systems in patients with advanced liver disease.
Timeline
March 2024: Resmetirom received FDA accelerated approval for noncirrhotic MASH.
August 2025: Semaglutide received FDA accelerated approval for the MASH population.
October 9-14, 2026: The comparative analysis was presented at the ACG 2026 meeting in Nashville.
Health Landscape
This analysis relies on the TriNetX Global Collaborative Network to fill gaps in long-term outcome data for newly approved liver treatments. It marks an effort to provide evidence for the management of MASLD and MASH as therapeutic options continue to evolve.
Patients currently managing MASH or MASLD may want to discuss how these different treatment options align with their cardiovascular health profiles. Because treatment paths are highly individualized, consult your physician to review your specific liver health and heart risk status.
The takeaway
This analysis highlights the potential cardiovascular differences between emerging MASH treatments. If you are being treated for MASLD or MASH, ask your doctor which therapy is best suited to both your liver and cardiovascular health needs.
Further reading
For more on managing heart risks, visit Heart Disease.
Live Poll
Do new clinical study results regarding heart disease benefits increase your trust in chronic condition treatments?
